(secondQuint)Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease.

 Multi-centre, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 as add-on to donepezil.

 The patient has probable Alzheimer's Disease consistent with the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.

.

 Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease@highlight

The purpose of this study is to accept or reject the hypothesis that Lu AE58054 improves cognition and functional outcomes in patients with moderate Alzheimer's Disease, already in treatment with donepezil.

